Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 September 2021 | Story Dr Nitha Ramnath
Prof Bonang Mohale.


The executive management of the University of the Free State (UFS) and the university community extend heartfelt congratulations to Prof Bonang Mohale on his appointment as President of Business Unity South Africa (BUSA). 

“Prof Mohale’s extensive expertise and experience in leadership roles, contributions to the growth of many multinational companies, and involvement in education and the business sector, will undoubtedly strengthen the ties between various sectors and civil society, and further contribute to the stabilisation and growth of South Africa,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor, in his congratulatory letter to Prof Mohale. 

BUSA’s role in influencing policy and legislative development for inclusive growth and employment, and in building an enabling environment for the creation of a vibrant, diverse, and globally competitive economy that harnesses the economic and human potential in South Africa, is well documented. This potential resides in our higher education institutions in the form of our students, future graduates, and graduates who are the building blocks for the development of South Africa. 

At a time when our country is facing a social and economic crisis, we are confident that BUSA will consider the perspectives across sectors with a view to creating partnerships, collaboration, and co-creation and further play an integral role in our higher education institutions for the benefit of our students. 

“Prof Mohale’s support to the UFS is appreciated, especially his role as Chancellor and his contribution towards our Thought-Leader and Global Citizen programmes, through which important national and global issues are addressed.
 
We wish Prof Mohale every success in his endeavours, particularly as President of BUSA,” said Prof Petersen.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept